Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Inflammation damages sweat ducts, causing sweat gland injury.

Composite biomaterials can precisely control immune responses for better disease treatment.

Modern lifestyles, including poor diet, stress, and long-term use of certain medications, hinder the body's ability to heal from inflammation, leading to chronic diseases.

Researchers found that certain miRNAs, which affect immune system regulation, are differently expressed in mice with a hair loss condition compared to healthy mice.

Nanotechnology can improve tissue healing by controlling immune responses.

NK cells play a role in skin diseases like eczema and psoriasis.

Age-related immune changes worsen Parkinson's disease, suggesting new treatment strategies.

Blocking IL-8 can reduce skin rashes from cancer treatment.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Enhancing immune response can improve cancer treatment effectiveness.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Regulatory T cells help heal skin wounds by reducing inflammation and promoting tissue repair.

A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.

Type 2 immunity helps control mite growth in hair follicles, preventing damage.

SIG-1451 could be a promising new treatment for atopic dermatitis.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Hidradenitis suppurativa might be a type of autoinflammatory skin disease.

Volatile organic compounds can cause inflammation and increase the risk of autoimmune diseases.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

Antihepcidin antibodies may treat inflammation-induced anemia by improving iron metabolism.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

The nail matrix has a reduced immune response, protecting it from autoimmunity.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.

Early recognition of skin issues in immunocompromised patients is crucial for better outcomes.